Immune checkpoint inhibitors (ICIs) (e.g., PD-1/PD-L1 inhibitors) can reduce T-cell exhaustion, reshape cytokine networks, and modulate tumor-associated macrophages (TAMs) in ways that enhance immune-mediated tumor clearance (14, 15). The gene discussed is PDCD1; the disease is neoplasm.